Tumor molecular profiling of responders and non-responders following pembrolizumab monotherapy in chemotherapy resistant advanced cervical cancer

Tumor molecular profiling of responders and non-responders following pembrolizumab monotherapy in chemotherapy resistant advanced cervical cancer

Optimal treatment for advanced cervical cancer after first line chemotherapy remains undefined. Immune checkpoint inhibition with pembrolizumab, a programmed cell death protein 1(PD-1) inhibitor, is under investigation. We analyzed the micro-environmental and molecular genetic profile of tumors from...

Full description

Bibliographic Details
Main Authors: N.Y.L. Ngoi, V. Heong, X.W. Lee, Y.Q. Huang, Y.L. Thian, B.A. Choo, D. Lim, Y.W. Lim, S.E. Lim, A. Ilancheran, R. Soong, D.S.P. Tan
Format: Article
Language:English
Published: Elsevier 2018-05-01
Series:Gynecologic Oncology Reports
Online Access:http://www.sciencedirect.com/science/article/pii/S2352578918300092

Internet

http://www.sciencedirect.com/science/article/pii/S2352578918300092

Similar Items